Ziccum

Executive Summary

Ziccum is a Swedish drug delivery company pioneering LaminarPace, a mass transfer drying system that converts liquid biopharmaceuticals and vaccines into thermostable, particle-engineered dry powders without heat stress or degradation. This technology addresses a critical bottleneck in the biologics and vaccine supply chain—the reliance on cold chain logistics—by enabling ambient-temperature storage and transport. Founded in 2016 and based in Lund, Ziccum targets next-generation biologics, including mRNA, viral vectors, and protein therapeutics, where traditional lyophilization or spray drying often causes activity loss. LaminarPace operates at ambient pressure and temperature, preserving the integrity of sensitive biomolecules while offering scalable, continuous processing. The company has not yet disclosed pipeline specifics or funding rounds, but its platform has garnered interest from pharma partners seeking to enhance vaccine stability and global access, particularly for low- and middle-income countries.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major vaccine developer for LaminarPace application in mRNA or viral vector drying40% success
• Q4 2026Series A funding round completion to accelerate commercialization70% success
• Q3 2026Publication of proof-of-concept data demonstrating dry powder stability for a model biologic50% success